UCB out-licenses six products to Actient.
M2 PHARMA-July 30, 2010-UCB out-licenses six products to Actient(C)2010 M2 COMMUNICATIONS
30 July 2010 - Belgian UCB SA (EBR: UCB) said Friday it has licensed US marketing rights to six pharmaceutical products to Actient Pharmaceuticals LLC, a US-based specialty pharmaceutical company, with an option for Actient to purchase those products.
Actient is a portfolio company of GTCR, a private equity firm based in Chicago.
In 2009, the six products achieved gross annual sales of approximately USD53m (EUR40.6m). Under the agreement, UCB will receive an upfront payment upon closing as well as future royalty payments.
This transaction is part of UCB's long-term strategy to become the patient-centric global biopharmaceutical leader focused on immunology and neurology, it said.
Products in the transaction include Edex (alprostadil for injection), Theo-24 (theophylline anhydrous), Semprex-D Capsules (acrivastine and pseudoephedrine hydrochloride), Levatol (penbutolol sulfate), Robaxin (methocarbamol tablets, USP) and Dilatrate-SR (isosorbide dinitrate). The product set will form the basis of a commercial platform upon which Actient will continue to license and acquire strategic pharmaceutical assets, UCB added.
(USD1 = EUR0.766)
((Comments on this story may be sent to email@example.com))